Eterna Therapeutics Inc. (ERNA)
After hours:
| Previous Close | 1.0700 |
| Open | 1.1000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.0100 - 1.1324 |
| 52 Week Range | 0.8400 - 2.6300 |
| Volume | |
| Avg. Volume | 26,121 |
| Market Cap | 5.519M |
| Beta (5Y Monthly) | 7.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.4300 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
TipRanksEterna, Factor announce license, collaboration agreement
Eterna Therapeutics and Factor Bioscience announced an exclusive license and collaboration agreement aimed at accelerating the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Under the terms of the agreement, Eterna has secured a worldwide, exclusive, non-transferable, royalty-bearing license, with the right to grant sublicenses, to develop and market certain induced pluripotent stem cell-based cell therapy products (in particular iPSC deriv
GlobeNewswireEterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license and collaboration agreement aimed at accelerating the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Under the terms of the agreement, Eterna has secured a worldwide, exclusive, non-transferable, royalty-bearing license, with the right to grant s
